Undifferentiated Sarcoma — Trials

Undifferentiated Sarcoma — Trials · CancerIndex

Clinical trials

Registered studies

58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05017103	Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study	terminated	Phase 2	6	M.D. Anderson Cancer CenterOTHER	1	Dec 11, 2024	clinicaltrials
NCT02601209	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma	terminated	Phase 1 / Phase 2	151	National Cancer Institute (NCI)NIH	1	Aug 23, 2022